# US 9,872,912 B2 · Method for treating pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,912 B2
- Document ID: US9872912B2
- Status: Granted
- Kind: B2
- Application number: 14/520,050
- Filed: 2014-10-21
- Published: 2015-12-10
- Granted: 2018-01-23
- Earliest claimed: 2014-06-04
- Assignees: China Medical University
- Applicants: China Medical University
- Inventors: Tzyy-Wen Chiou; Horng-Jyh Harn; Shinn-Zong Lin; Yi-Wen Chou; Mao-Hsuan Huang
- Web page: https://patentgrep.com/patent/US9872912B2

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/365: Lactones
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.

## Claims

### Claim 1

A method for treating pancreatic cancer comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical formulation further comprises a biocompatible polymer matrix, and (Z)-butylidenephthalide is included in the matrix.

### Claim 3 (depends on 2)

The method of claim 2, wherein the biocompatible polymer matrix is selected from the group consisting of poly(lactic-co-glycolic acid), chitosan, collagen, a hydrogel, a polyanhydride, and combinations thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the biocompatible polymer matrix is a polyanhydride.

### Claim 5 (depends on 4)

The method of claim 4, wherein the polyanhydride is a copolymer of monomer (A) and monomer (B):
wherein,
m is an integer ranging from 1 to 10, and
n is an integer ranging from 0 to 20.

### Claim 6 (depends on 5)

The method of claim 5, wherein m is an integer ranging from 2 to 8 and n is an integer ranging from 3 to 10.

### Claim 7 (depends on 5)

The method of claim 5, wherein the polyanhydride is a block copolymer of monomer (A) and monomer (B).

### Claim 8 (depends on 6)

The method of claim 6, wherein the monomer (A) is bis(p-carboxy-phenoxy)propane and monomer (B) is sebacic acid.

### Claim 9 (depends on 5)

The method of claim 5, wherein the molar ratio of the monomer (A) and monomer (B) ranges from about 1:2 to about 1:10.

### Claim 10 (depends on 9)

The method of claim 9, wherein the molar ratio of the monomer (A) and monomer (B) ranges from about 1:3 to about 1:6.

### Claim 11 (depends on 1)

The method of claim 1, wherein the concentration of (Z)-butylidenephthalide in the pharmaceutical formulation is about 1% by weight to about 40% by weight.

### Claim 12 (depends on 11)

The method of claim 11, wherein the concentration of (Z)-butylidenephthalide is about 2% by weight to about 30% by weight.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutical formulation is provided as a wafer, powder, a membrane, a flake, a rod, a microparticle, and nanoparticle, a paste, or a gel.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pharmaceutical formulation is provided as a wafer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the pharmaceutical formulation is administered by at least one of subcutaneous implantation, interstitial implant, and intra-pancreas implantation.

### Claim 16 (depends on 1)

The method of claim 1, wherein the pharmaceutical formulation is administered at an amount ranging from about 10 mg (as (Z)-butylidenephthalide)/kg-body weight to about 1,000 mg (as (Z)-butylidenephthalide)/kg-body weight per day.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pharmaceutical formulation is administered at an amount ranging from about 50 mg (as (Z)-butylidenephthalide)/kg-body weight to about 500 mg (as (Z)-butylidenephthalide)/kg-body weight per day.

### Claim 18 (depends on 8)

The method of claim 8, wherein the molar ratio of the monomer (A) and monomer (B) is about 1:4.